Tevogen Bio (TVGN) Projected to Post Quarterly Earnings on Thursday

Tevogen Bio (NASDAQ:TVGN) is projected to issue its results before the market opens on Thursday, August 13th. Analysts expect Tevogen Bio to announce earnings of ($2.5350) per share for the quarter.

Tevogen Bio (NASDAQ:TVGN) last issued its quarterly earnings data on Friday, May 15th. The company reported ($1.61) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.64) by $1.03.

Tevogen Bio Stock Down 2.1%

Shares of NASDAQ:TVGN opened at $6.85 on Thursday. Tevogen Bio has a 12-month low of $3.64 and a 12-month high of $55.00. The business has a 50 day moving average of $7.26 and a 200-day moving average of $8.78. The stock has a market cap of $28.90 million, a PE ratio of -1.49 and a beta of 0.18.

Institutional Investors Weigh In On Tevogen Bio

Large investors have recently added to or reduced their stakes in the stock. Bridgeway Capital Management LLC raised its holdings in Tevogen Bio by 66.7% in the 3rd quarter. Bridgeway Capital Management LLC now owns 82,500 shares of the company’s stock valued at $65,000 after acquiring an additional 33,000 shares in the last quarter. Deutsche Bank AG increased its position in shares of Tevogen Bio by 304.1% in the fourth quarter. Deutsche Bank AG now owns 173,734 shares of the company’s stock worth $57,000 after purchasing an additional 130,738 shares during the period. Finally, Goldman Sachs Group Inc. increased its position in shares of Tevogen Bio by 126.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 273,694 shares of the company’s stock worth $91,000 after purchasing an additional 152,572 shares during the period.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Tevogen Bio in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus price target of $100.00.

About Tevogen Bio

Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).

In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.